Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: amlodipine besylate; telmisartan

« Back to Dashboard
Amlodipine besylate; telmisartan is the generic ingredient in two branded drugs marketed by Lupin Ltd, Mylan Pharms Inc, Torrent Pharms Ltd, and Boehringer Ingelheim, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

There are forty-seven drug master file entries for amlodipine besylate; telmisartan. One supplier is listed for this compound.

Summary for Generic Name: amlodipine besylate; telmisartan

Drug Master File Entries: see list47
Suppliers / Packaging: see list4

Pharmacology for Ingredient: amlodipine besylate; telmisartan

Clinical Trials for: amlodipine besylate; telmisartan

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
Status: Completed Condition: Hypertension

CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)
Status: Completed Condition: Hypertension; Hyperlipidemia

Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine
Status: Completed Condition: Essential Hypertension; Hyperlipidemia

Telmisartan, Amlodipine and Combination in Healthy Subjects
Status: Completed Condition: Healthy

The Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine
Status: Completed Condition: Hypertension; Hyperlipidemia

A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients
Status: Completed Condition: Hypertension; Obesity

CKD-828 (80/5mg) Pharmacokinetic Study
Status: Completed Condition: Hypertension

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd
amlodipine besylate; telmisartan
TABLET;ORAL201586-004Jan 8, 2014RXNo<disabled><disabled>
Mylan Pharms Inc
amlodipine besylate; telmisartan
TABLET;ORAL202516-002Aug 26, 2014RXNo<disabled><disabled>
Lupin Ltd
amlodipine besylate; telmisartan
TABLET;ORAL201586-001Jan 8, 2014RXNo<disabled><disabled>
Boehringer Ingelheim
amlodipine besylate; telmisartan
TABLET;ORAL022401-001Oct 16, 2009RXNo<disabled><disabled>
Boehringer Ingelheim
amlodipine besylate; telmisartan
TABLET;ORAL022401-004Oct 16, 2009RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn